Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma

Akkök, Çiğdem Akalın; Hervig, Tor; Stamnesfet, S.; Nesthus, Ingerid; Melve, Guro Kristin; Lassalle, Philippe; Bruserud, Øystein

doi:10.3109/14653249.2011.605117

Cited by 9 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant difference in serum ANG levels was noted between the subgroups ( p = 0.12). Regarding serum ANG levels in patients with specific types of cancer, patients with colorectal cancer (CRC) [ 27 , 28 ] (pooled SMD = 1.542, 95% CI = 0.496 to 2.587, p = 0.004), acute myelogenous leukemia (AML) [ 29 – 32 ] (pooled SMD = 1.319, 95% CI = 0.574 to 2.064, p = 0.001), multiple myeloma (MM) [ 33 – 37 ] (pooled SMD = 0.822, 95% CI = 0.604 to 1.040, p < 0.001), and myelodysplastic syndromes (MDSs) [ 29 , 38 ] (pooled SMD = 0.616, 95% CI = 0.254 to 0.978, p = 0.001) had significantly higher serum ANG levels than healthy controls; however, patients with hepatocellular cancer (HCC) [ 39 – 41 ] ( p = 0.249), breast cancer [ 12 , 19 , 42 , 43 ] ( p = 0.443), non-Hodgkin lymphomas (NHLs) [ 44 , 45 ] ( p = 0.257), and melanoma [ 46 , 47 ] ( p = 0.550) did not have significantly higher serum ANG levels than healthy controls (Figure S2 ). According to these results, we concluded that serum ANG levels are upregulated in patients with cancer, especially patients with CRC, AML, MM, melanoma, and MDSs.…”

Section: Resultsmentioning

confidence: 99%

The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis

Cai

Zhou

et al. 2018

Disease Markers

View full text Add to dashboard Cite

Background Angiogenin (ANG) is a multifunctional angiogenic protein that participates in both normal development and diseases. Abnormal serum ANG levels are commonly reported in various diseases. However, whether ANG can serve as a diagnostic or prognostic marker for different diseases remains a matter of debate. Methods Here, we performed a systematic review and meta-analysis of the literature utilizing PubMed, Web of Science, and Scopus search engines to identify all publications comparing plasma or serum ANG levels between patients with different diseases and healthy controls, as were studies evaluating circulating ANG levels in healthy populations, pregnant women, or other demographic populations. Results This study demonstrated that the serum ANG concentration in healthy populations was 336.14 ± 142.83 ng/ml and remained relatively stable in different populations and regions. We noted no significant differences in serum ANG levels between patients and healthy controls, except in cases in which patients suffered from cancer or cardiovascular diseases. The serum ANG concentrations were significantly higher in patients who developed colorectal cancer, acute myeloid leukemia, multiple myeloma, myelodysplastic syndromes, and heart failure than those in healthy controls. Conclusion ANG has the potential of being a serum biomarker for cancers and cardiovascular diseases.

show abstract

Section: Resultsmentioning

confidence: 99%

The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis

Cai

Zhou

et al. 2018

Disease Markers

View full text Add to dashboard Cite

show abstract

“…The patient characteristics are presented in Table 1. All patients received premobilization therapy including either a proteasome inhibitor or an IMiD; this induction treatment was followed by stem cell mobilization using cyclophosphamide plus G-CSF [47, 48]. The stem cell grafts were cryopreserved in 5% dimethyl sulfoxide and stored in liquid nitrogen until reinfusion [49, 50].…”

Section: Methodsmentioning

confidence: 99%

Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

et al. 2019

Self Cite

View full text Add to dashboard Cite

BackgroundInduction therapy of multiple myeloma patients prior to autologous stem cell transplantation has changed from conventional chemotherapy to treatment based on proteasome inhibitors or immunomodulatory drugs. We used flow cytometry to analyze total monocyte and monocyte subset (classical, intermediate and non-classical monocytes) peripheral blood levels before and following auto-transplantation for a consecutive group of myeloma patients who had received the presently used induction therapy.ResultsThe patients showed normal total monocyte concentrations after induction/stem cell mobilization, but the concentrations of classical monocytes were increased compared with healthy controls. Melphalan conditioning reduced the levels of total CD14+ as well as classical and non-classical monocytes, whereas intermediate monocytes were not affected. Thus, melphalan has a non-random effect on monocyte subsets. Melphalan had a stronger effect on total and classical monocyte concentrations for those patients who had received induction therapy including immunomodulatory drugs. Total monocytes and monocyte subset concentrations decreased during the period of pancytopenia, but monocyte reconstitution occurred before hematopoietic reconstitution. However, the fractions of various monocyte subsets varied considerably between patients.ConclusionsThe total level of circulating monocytes is normalized early after auto-transplantation for multiple myeloma, but pre- and post-transplant levels of various monocyte subsets show considerable variation between patients.

show abstract

“…In note, biomarker studies have suggested that diagnostic or therapeutic procedures, e.g. peripheral blood stem cell apheresis, may also have pro-inflammatory consequences (19). Section 1.4, p. 10 will describe in detail individual cytokines, as well as other soluble mediators (i.e.…”

Section: The Cytokine Network In Inflammationmentioning

confidence: 99%

Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma

et al. 2013

Self Cite

View full text Add to dashboard Cite

show abstract

Effects of peripheral blood stem cell apheresis on systemic cytokine levels in patients with multiple myeloma

Cited by 9 publications

References 25 publications

The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis

The Potential of Angiogenin as a Serum Biomarker for Diseases: Systematic Review and Meta-Analysis

Circulating monocyte subsets in multiple myeloma patients receiving autologous stem cell transplantation – a study of the preconditioning status and the course until posttransplant reconstitution for a consecutive group of patients

Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma

Contact Info

Product

Resources

About